Sw620

The human CRC cell lines, COLO 205, COLO 320HSR, DLD-1, HCT 116, HCT-8, HT-29, SW480, SW620, and LoVo were purchased from the Korean Cell Line Bank (KCLB, Seoul, Republic of Korea). The RKO CRC cell line was from American Type Culture Collection (ATCC, Manassas, VA, USA). Cell lines were cultured in RPMI 1640 (Welgene, Daegu, Korea) or DMEM (Welgene) medium containing 10% heat-inactivated fetal bovine serum (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) in a 37°C incubator with a humidified atmosphere of 5% CO₂. DLD-1 isogenic cell lines wt PIK3CA (351) and mt PIK3CA (353) were provided by Dr Bert Vogelstein, and cultured in McCoy’s medium (Welgene) supplemented with 10% FBS and penicillin/streptomycin (Welgene).

The human CRC cell lines, HCT116, SW480, SW620 and LS174T, were purchased from the Korean Cell Line Bank (KCLB nos. #10247, #10228, #10227 and #10188, respectively), and cultured in RPMI-1640 medium, supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) at 37°C in a 5% CO₂ incubator. HT29 cells (KCLB no. #30038), which originate from AN adenocarcinoma of the rectosigmoid part of the intestine (30 (link)), were cultured in RPMI-1640 medium supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.). KM12SM cells (KCLB no. #80016) were cultured in DMEM supplemented with 10% FBS. For STAT3 inhibitor treatment, the cells were treated with stattic (5 µM; Selleck Chemicals LLC). For EDNRA inhibitor treatment, the CRC cells were treated with macitentan (2 or 10 µM; Merck KGaA).